Nebivolol decreases systemic oxidative stress in healthy volunteers
Aims Nebivolol is a selective, vasodilatory β1‐adrenergic receptor antagonist which has been suggested to possess additional antioxidative properties. The aim of the present study was to assess the actions of nebivolol in antihypertensive doses on systemic oxidative stress in healthy volunteers, ref...
Gespeichert in:
| Veröffentlicht in: | British journal of clinical pharmacology 2000-10, Vol.50 (4), p.377-379 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 379 |
|---|---|
| container_issue | 4 |
| container_start_page | 377 |
| container_title | British journal of clinical pharmacology |
| container_volume | 50 |
| creator | Troost, R. Schwedhelm, E. Rojczyk, S. Tsikas, D. Frölich, J. C. |
| description | Aims
Nebivolol is a selective, vasodilatory β1‐adrenergic receptor antagonist which has been suggested to possess additional antioxidative properties. The aim of the present study was to assess the actions of nebivolol in antihypertensive doses on systemic oxidative stress in healthy volunteers, reflected by 24 h urinary excretion of 8‐iso‐PGF2α.
Methods
In a double‐blind, cross‐over study, 12 healthy volunteers received 5 mg nebivolol once daily or placebo for a total of 7 days, separated by a wash out period of 2 weeks. After each treatment period 24 h urinary excretion of 8‐iso‐PGF2α was determined by gas chromatography‐tandem mass spectrometry.
Results
After the 7 day treatment period nebivolol decreased significantly urinary excretion of 8‐iso‐PGF2α by 24% from 55.3 ± 5.1 pmol mmol−1 creatinine during the placebo period to 42.3 ± 4.7 pmol mmol−1 creatinine (mean ± s.e. mean, P = 0.01), a mean decrease of 13 pmol mmol−1 creatinine (95% CI: −22.8; −3.1).
Conclusions
Our data show for the first time that nebivolol decreases systemic oxidative stress in young healthy volunteers. |
| doi_str_mv | 10.1046/j.1365-2125.2000.00258.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2014994</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72296031</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5648-7f7fe092aed31cb4d49719b993349f81e5cf5b802c30902747247e64e9a9d7d43</originalsourceid><addsrcrecordid>eNqNkU-P0zAQxS3Eii2Fr4ByQNwSxv-SWEJIbMUC0go4wNlynAl15SaLJy3tt9-EVrvsjZMtze-9Gb3HWMah4KDKt5uCy1LnggtdCAAoAISui8MTtrgfPGULkFDmWmh-yZ4TbQC45KV-xi45h4koxYKtvmIT9kMcYtaiT-gIKaMjjbgNPhsOoXVj2GNGY0KiLPTZGl0c18dsEu36ETHRC3bRuUj48vwu2c_rjz9Wn_Obb5--rD7c5F6Xqs6rruoQjHDYSu4b1SpTcdMYI6UyXc1R-043NQgvwYCoVCVUhaVC40xbtUou2fuT7-2u2WLrsR-Ti_Y2ha1LRzu4YB9P-rC2v4a9FcCVMbPBm7NBGn7vkEa7DeQxRtfjsCNbCWFKkHwC6xPo00CUsLtfwsHODdiNnYO2c9B2bsD-bcAeJumrf498EJ4jn4DXZ8CRd7FLrveBHrj50imTJXt3wv6EiMf_3m-vVt-nj7wDGHqiVg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72296031</pqid></control><display><type>article</type><title>Nebivolol decreases systemic oxidative stress in healthy volunteers</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via Wiley Online Library</source><source>Wiley Online Library (Open Access Collection)</source><creator>Troost, R. ; Schwedhelm, E. ; Rojczyk, S. ; Tsikas, D. ; Frölich, J. C.</creator><creatorcontrib>Troost, R. ; Schwedhelm, E. ; Rojczyk, S. ; Tsikas, D. ; Frölich, J. C.</creatorcontrib><description>Aims
Nebivolol is a selective, vasodilatory β1‐adrenergic receptor antagonist which has been suggested to possess additional antioxidative properties. The aim of the present study was to assess the actions of nebivolol in antihypertensive doses on systemic oxidative stress in healthy volunteers, reflected by 24 h urinary excretion of 8‐iso‐PGF2α.
Methods
In a double‐blind, cross‐over study, 12 healthy volunteers received 5 mg nebivolol once daily or placebo for a total of 7 days, separated by a wash out period of 2 weeks. After each treatment period 24 h urinary excretion of 8‐iso‐PGF2α was determined by gas chromatography‐tandem mass spectrometry.
Results
After the 7 day treatment period nebivolol decreased significantly urinary excretion of 8‐iso‐PGF2α by 24% from 55.3 ± 5.1 pmol mmol−1 creatinine during the placebo period to 42.3 ± 4.7 pmol mmol−1 creatinine (mean ± s.e. mean, P = 0.01), a mean decrease of 13 pmol mmol−1 creatinine (95% CI: −22.8; −3.1).
Conclusions
Our data show for the first time that nebivolol decreases systemic oxidative stress in young healthy volunteers.</description><identifier>ISSN: 0306-5251</identifier><identifier>EISSN: 1365-2125</identifier><identifier>DOI: 10.1046/j.1365-2125.2000.00258.x</identifier><identifier>PMID: 11012562</identifier><identifier>CODEN: BCPHBM</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Adult ; Antihypertensive Agents - pharmacology ; Benzopyrans - pharmacology ; Biological and medical sciences ; Cardiovascular system ; Cross-Over Studies ; Dinoprost - analogs & derivatives ; Dinoprost - urine ; Double-Blind Method ; Ethanolamines - pharmacology ; F2-Isoprostanes ; Female ; healthy volunteers ; Humans ; Male ; Medical sciences ; Miscellaneous ; Nebivolol ; oxidative stress ; Oxidative Stress - drug effects ; Oxidative Stress - physiology ; Pharmacology. Drug treatments ; Short Reports ; β‐adrenoceptor antagonists</subject><ispartof>British journal of clinical pharmacology, 2000-10, Vol.50 (4), p.377-379</ispartof><rights>2000 INIST-CNRS</rights><rights>2000 Blackwell Science Ltd 2000</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5648-7f7fe092aed31cb4d49719b993349f81e5cf5b802c30902747247e64e9a9d7d43</citedby><cites>FETCH-LOGICAL-c5648-7f7fe092aed31cb4d49719b993349f81e5cf5b802c30902747247e64e9a9d7d43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-2125.2000.00258.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-2125.2000.00258.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1499499$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11012562$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Troost, R.</creatorcontrib><creatorcontrib>Schwedhelm, E.</creatorcontrib><creatorcontrib>Rojczyk, S.</creatorcontrib><creatorcontrib>Tsikas, D.</creatorcontrib><creatorcontrib>Frölich, J. C.</creatorcontrib><title>Nebivolol decreases systemic oxidative stress in healthy volunteers</title><title>British journal of clinical pharmacology</title><addtitle>Br J Clin Pharmacol</addtitle><description>Aims
Nebivolol is a selective, vasodilatory β1‐adrenergic receptor antagonist which has been suggested to possess additional antioxidative properties. The aim of the present study was to assess the actions of nebivolol in antihypertensive doses on systemic oxidative stress in healthy volunteers, reflected by 24 h urinary excretion of 8‐iso‐PGF2α.
Methods
In a double‐blind, cross‐over study, 12 healthy volunteers received 5 mg nebivolol once daily or placebo for a total of 7 days, separated by a wash out period of 2 weeks. After each treatment period 24 h urinary excretion of 8‐iso‐PGF2α was determined by gas chromatography‐tandem mass spectrometry.
Results
After the 7 day treatment period nebivolol decreased significantly urinary excretion of 8‐iso‐PGF2α by 24% from 55.3 ± 5.1 pmol mmol−1 creatinine during the placebo period to 42.3 ± 4.7 pmol mmol−1 creatinine (mean ± s.e. mean, P = 0.01), a mean decrease of 13 pmol mmol−1 creatinine (95% CI: −22.8; −3.1).
Conclusions
Our data show for the first time that nebivolol decreases systemic oxidative stress in young healthy volunteers.</description><subject>Adult</subject><subject>Antihypertensive Agents - pharmacology</subject><subject>Benzopyrans - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>Cross-Over Studies</subject><subject>Dinoprost - analogs & derivatives</subject><subject>Dinoprost - urine</subject><subject>Double-Blind Method</subject><subject>Ethanolamines - pharmacology</subject><subject>F2-Isoprostanes</subject><subject>Female</subject><subject>healthy volunteers</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Nebivolol</subject><subject>oxidative stress</subject><subject>Oxidative Stress - drug effects</subject><subject>Oxidative Stress - physiology</subject><subject>Pharmacology. Drug treatments</subject><subject>Short Reports</subject><subject>β‐adrenoceptor antagonists</subject><issn>0306-5251</issn><issn>1365-2125</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU-P0zAQxS3Eii2Fr4ByQNwSxv-SWEJIbMUC0go4wNlynAl15SaLJy3tt9-EVrvsjZMtze-9Gb3HWMah4KDKt5uCy1LnggtdCAAoAISui8MTtrgfPGULkFDmWmh-yZ4TbQC45KV-xi45h4koxYKtvmIT9kMcYtaiT-gIKaMjjbgNPhsOoXVj2GNGY0KiLPTZGl0c18dsEu36ETHRC3bRuUj48vwu2c_rjz9Wn_Obb5--rD7c5F6Xqs6rruoQjHDYSu4b1SpTcdMYI6UyXc1R-043NQgvwYCoVCVUhaVC40xbtUou2fuT7-2u2WLrsR-Ti_Y2ha1LRzu4YB9P-rC2v4a9FcCVMbPBm7NBGn7vkEa7DeQxRtfjsCNbCWFKkHwC6xPo00CUsLtfwsHODdiNnYO2c9B2bsD-bcAeJumrf498EJ4jn4DXZ8CRd7FLrveBHrj50imTJXt3wv6EiMf_3m-vVt-nj7wDGHqiVg</recordid><startdate>200010</startdate><enddate>200010</enddate><creator>Troost, R.</creator><creator>Schwedhelm, E.</creator><creator>Rojczyk, S.</creator><creator>Tsikas, D.</creator><creator>Frölich, J. C.</creator><general>Blackwell Science Ltd</general><general>Blackwell Science</general><general>Blackwell Science Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>200010</creationdate><title>Nebivolol decreases systemic oxidative stress in healthy volunteers</title><author>Troost, R. ; Schwedhelm, E. ; Rojczyk, S. ; Tsikas, D. ; Frölich, J. C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5648-7f7fe092aed31cb4d49719b993349f81e5cf5b802c30902747247e64e9a9d7d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adult</topic><topic>Antihypertensive Agents - pharmacology</topic><topic>Benzopyrans - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>Cross-Over Studies</topic><topic>Dinoprost - analogs & derivatives</topic><topic>Dinoprost - urine</topic><topic>Double-Blind Method</topic><topic>Ethanolamines - pharmacology</topic><topic>F2-Isoprostanes</topic><topic>Female</topic><topic>healthy volunteers</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Nebivolol</topic><topic>oxidative stress</topic><topic>Oxidative Stress - drug effects</topic><topic>Oxidative Stress - physiology</topic><topic>Pharmacology. Drug treatments</topic><topic>Short Reports</topic><topic>β‐adrenoceptor antagonists</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Troost, R.</creatorcontrib><creatorcontrib>Schwedhelm, E.</creatorcontrib><creatorcontrib>Rojczyk, S.</creatorcontrib><creatorcontrib>Tsikas, D.</creatorcontrib><creatorcontrib>Frölich, J. C.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Troost, R.</au><au>Schwedhelm, E.</au><au>Rojczyk, S.</au><au>Tsikas, D.</au><au>Frölich, J. C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nebivolol decreases systemic oxidative stress in healthy volunteers</atitle><jtitle>British journal of clinical pharmacology</jtitle><addtitle>Br J Clin Pharmacol</addtitle><date>2000-10</date><risdate>2000</risdate><volume>50</volume><issue>4</issue><spage>377</spage><epage>379</epage><pages>377-379</pages><issn>0306-5251</issn><eissn>1365-2125</eissn><coden>BCPHBM</coden><abstract>Aims
Nebivolol is a selective, vasodilatory β1‐adrenergic receptor antagonist which has been suggested to possess additional antioxidative properties. The aim of the present study was to assess the actions of nebivolol in antihypertensive doses on systemic oxidative stress in healthy volunteers, reflected by 24 h urinary excretion of 8‐iso‐PGF2α.
Methods
In a double‐blind, cross‐over study, 12 healthy volunteers received 5 mg nebivolol once daily or placebo for a total of 7 days, separated by a wash out period of 2 weeks. After each treatment period 24 h urinary excretion of 8‐iso‐PGF2α was determined by gas chromatography‐tandem mass spectrometry.
Results
After the 7 day treatment period nebivolol decreased significantly urinary excretion of 8‐iso‐PGF2α by 24% from 55.3 ± 5.1 pmol mmol−1 creatinine during the placebo period to 42.3 ± 4.7 pmol mmol−1 creatinine (mean ± s.e. mean, P = 0.01), a mean decrease of 13 pmol mmol−1 creatinine (95% CI: −22.8; −3.1).
Conclusions
Our data show for the first time that nebivolol decreases systemic oxidative stress in young healthy volunteers.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>11012562</pmid><doi>10.1046/j.1365-2125.2000.00258.x</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0306-5251 |
| ispartof | British journal of clinical pharmacology, 2000-10, Vol.50 (4), p.377-379 |
| issn | 0306-5251 1365-2125 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2014994 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via Wiley Online Library; Wiley Online Library (Open Access Collection) |
| subjects | Adult Antihypertensive Agents - pharmacology Benzopyrans - pharmacology Biological and medical sciences Cardiovascular system Cross-Over Studies Dinoprost - analogs & derivatives Dinoprost - urine Double-Blind Method Ethanolamines - pharmacology F2-Isoprostanes Female healthy volunteers Humans Male Medical sciences Miscellaneous Nebivolol oxidative stress Oxidative Stress - drug effects Oxidative Stress - physiology Pharmacology. Drug treatments Short Reports β‐adrenoceptor antagonists |
| title | Nebivolol decreases systemic oxidative stress in healthy volunteers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T08%3A12%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nebivolol%20decreases%20systemic%20oxidative%20stress%20in%20healthy%20volunteers&rft.jtitle=British%20journal%20of%20clinical%20pharmacology&rft.au=Troost,%20R.&rft.date=2000-10&rft.volume=50&rft.issue=4&rft.spage=377&rft.epage=379&rft.pages=377-379&rft.issn=0306-5251&rft.eissn=1365-2125&rft.coden=BCPHBM&rft_id=info:doi/10.1046/j.1365-2125.2000.00258.x&rft_dat=%3Cproquest_pubme%3E72296031%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72296031&rft_id=info:pmid/11012562&rfr_iscdi=true |